Truist Financial
CORT icon

Truist Financial’s Corcept Therapeutics CORT Stock Holding History

Truist Financial’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.8M Sell
15,605
-844
-5% -$90.8K ﹤0.01% 1444
2026
Q2 		$1.43M Buy
16,449
+7,879
+92% +$476K ﹤0.01% 1565
2026
Q1 		$345K Sell
8,570
-500
-6% -$18.7K ﹤0.01% 2315
2025
Q4 		$316K Buy
9,070
+5,702
+169% +$448K ﹤0.01% 2292
2025
Q3 		$280K Buy
3,368
+59
+2% +$4.27K ﹤0.01% 2361
2025
Q2 		$243K Buy
3,309
+631
+24% +$45.7K ﹤0.01% 2319
2025
Q1 		$306K Buy
+2,678
New +$163K ﹤0.01% 2136
2024
Q2 		– Sell
-9,246
Closed -$233K – 2663
2024
Q1 		$233K Sell
9,246
-5,507
-37% -$130K ﹤0.01% 2416
2023
Q4 		$479K Sell
14,753
-3,776
-20% -$104K ﹤0.01% 2004
2023
Q3 		$505K Buy
18,529
+8,711
+89% +$252K ﹤0.01% 1924
2023
Q2 		$218K Sell
9,818
-21,580
-69% -$497K ﹤0.01% 2409
2023
Q1 		$680K Buy
31,398
+8,861
+39% +$194K ﹤0.01% 1782
2022
Q4 		$458K Buy
+22,537
New +$565K ﹤0.01% 2021
2022
Q3 		– Sell
-15,295
Closed -$364K – 2541
2022
Q2 		$364K Hold
15,295
– – ﹤0.01% 2098
2022
Q1 		$344K Hold
15,295
– – ﹤0.01% 2228
2021
Q4 		$303K Buy
+15,295
New +$310K ﹤0.01% 2351
2020
Q4 		– Sell
-28,080
Closed -$489K – 2560
2020
Q3 		$489K Sell
28,080
-4,540
-14% -$72.4K ﹤0.01% 1749
2020
Q2 		$549K Sell
32,620
-3,829
-11% -$53.8K ﹤0.01% 1571
2020
Q1 		$433K Sell
36,449
-4,133
-10% -$51.1K ﹤0.01% 1640
2019
Q4 		$491K Buy
+40,582
New +$565K ﹤0.01% 1881

Other funds holding CORT

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Ingalls & Snyder LLC
Ingalls & Snyder LLC New York $3.91B AUM 60.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Parallel Advisors
Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

Truist Financial's CORT Position: Q3 2026 in Review

Truist Financial reduced its Corcept Therapeutics (CORT) stake by 5.1% in Q3 2026, selling an estimated $90.8K and leaving 15,605 shares worth $1.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1444.

Truist Financial first reported a position in CORT in Q4 2019 and has held it in 20 quarters since. 403 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • Truist Financial held 15,605 shares of Corcept Therapeutics worth $1.8M as of Q3 2026.
  • Truist Financial sold 844 Corcept Therapeutics shares in Q3 2026, an estimated $90.8K.
  • Corcept Therapeutics made up ﹤0.01% of Truist Financial's portfolio in Q3 2026, its #1444 holding.
  • Truist Financial first reported a position in Corcept Therapeutics in Q4 2019 and has held it in 20 quarters since.
  • 403 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Truist Financial's 13F filing for Q3 2026, filed 30 Oct 2026.